|
Duplex Sequencing - Future of mutagenicity assessment
|
|
3
|
607
|
January 23, 2024
|
|
Bard responds to Nitrosamine Risk Assessment scheme
|
|
1
|
725
|
January 16, 2024
|
|
Potential Event with USP & Health Authorities
|
|
8
|
729
|
February 2, 2024
|
|
QSAR Models - Ames/QSAR International Challenge Project - 21 teams from 11 countries
|
|
0
|
474
|
December 12, 2023
|
|
Nitrosamine Risk Assessment for Purified Water Used in Manufacturing for Pilot Bio/Clinical Trial Batches
|
|
2
|
1255
|
October 22, 2023
|
|
Nitrosamines risk assessments for Topical herbal extracts
|
|
1
|
509
|
September 20, 2023
|
|
Enhanced Ames Test Conditions for N-nitrosamines (Q&A Rev.16)
|
|
9
|
3096
|
September 13, 2023
|
|
Quantitation of Reactive Nitrosating Agents in Pharmaceutical Excipients for N‑Nitrosamine Risk Assessments
|
|
4
|
1218
|
September 7, 2023
|
|
Forced Degradation and the NAP test
|
|
3
|
698
|
September 2, 2023
|
|
Potency score for protected hydroxy group
|
|
2
|
460
|
August 22, 2023
|
|
Risk Assessemento of Nitrosamines in soft capsule
|
|
6
|
1293
|
August 16, 2023
|
|
On the Risk of Nitrosamine Contamination during blister packaging
|
|
2
|
1004
|
August 10, 2023
|
|
N-Nitroso Betahistine formation
|
|
2
|
627
|
July 28, 2023
|
|
Nitrosamines and bioequivalence studies
|
|
4
|
677
|
July 20, 2023
|
|
Low Nitrite Excipients - it’s happening
|
|
2
|
967
|
June 30, 2023
|
|
Nitrosamine Risk Assessment for Drug Product Manufacturer with 50+ APIs
|
|
4
|
661
|
May 4, 2023
|
|
Instem SOT 2023 Presentation on Assessing N-nitrosamines Potency Classes
|
|
1
|
667
|
May 2, 2023
|
|
A Consideration of the Extent That Tertiary Amines Can Form N-Nitroso Dialkylamines in Pharmaceutical Products
|
|
1
|
1178
|
April 25, 2023
|
|
NDMA formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product
|
|
0
|
757
|
March 24, 2023
|
|
Nitrosamines in topical products
|
|
3
|
1043
|
March 9, 2023
|
|
Formation of Dialkyl-N-nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation
|
|
6
|
1254
|
February 25, 2023
|
|
Anybody has working with a Gliclazide nitrosamine?
|
|
3
|
1084
|
February 14, 2023
|
|
IPEC Europe announces the availability of the revised “Questionnaire for Excipient Nitrosamines Risk Evaluation” (Version 4, 2022)
|
|
11
|
1680
|
February 14, 2023
|
|
Lhasa Tutorial Vid on new Mirabilis 4.0
|
|
2
|
557
|
January 31, 2023
|
|
What to do with Nitrite content reported by Excipients?
|
|
0
|
650
|
January 25, 2023
|
|
What's your experience on API risk assessments?
|
|
4
|
558
|
November 25, 2022
|
|
Checklist for EMA Q&A Q4
|
|
0
|
488
|
July 30, 2022
|
|
Fate purge study
|
|
0
|
409
|
July 14, 2022
|
|
Sufficient AMES test, parameters
|
|
6
|
1258
|
July 13, 2022
|
|
Como conducir El Análisis de Riesgo?
|
|
0
|
386
|
May 9, 2022
|